Literature DB >> 21671771

Expression of hypoxia-inducible factors, regulators, and target genes in congenital diaphragmatic hernia patients.

Irene W J M van der Horst1, Prapapan Rajatapiti, Paul van der Voorn, Francien H van Nederveen, Dick Tibboel, Robbert Rottier, Irwin Reiss, Ronald R de Krijger.   

Abstract

Congenital diaphragmatic hernia (CDH) is associated with lung hypoplasia and pulmonary hypertension and has high morbidity and mortality rates. The cause and pathophysiology of CDH are not fully understood. However, impaired angiogenesis appears to play an important role in the pathophysiology of CDH. Therefore, we examined different components of an important pathway in angiogenesis: hypoxia-inducible factors (HIFs); HIF regulators von Hippel-Lindau (VHL) and prolyl 3-hydroxylase (PHD3); and HIF target genes vascular endothelial growth factor A ( VEGF-A ) and vascular endothelial growth factor receptor 2 ( VEGFR-2 ). Quantitative polymerase chain reaction of lung tissue showed a significantly decreased expression of VEGF-A mRNA in the alveolar stage of lung development in CDH patients compared with matched control patients. In the canalicular stage, no differences for VEGF-A were seen between the lungs of CDH patients and those of control patients. Other components of angiogenesis (VHL, HIF-1α, HIF-2α, HIF-3α, VEGFR-2 mRNA, PHD3 protein) that were analyzed showed no differences in expression between CDH and control patients, independent of the developmental stage. A lower expression of VEGF mRNA in CDH patients in the alveolar stage, possibly as a result of downregulation of HIF-2α might indicate a role for these factors in the pathophysiology of CDH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21671771     DOI: 10.2350/09-09-0705-OA.1

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  6 in total

1.  Heparin impairs angiogenic signaling and compensatory lung growth after left pneumonectomy.

Authors:  Duy T Dao; Lorenzo Anez-Bustillos; Jared Ourieff; Amy Pan; Paul D Mitchell; Hiroko Kishikawa; Gillian L Fell; Meredith A Baker; Randolph S Watnick; Hong Chen; Thomas E Hamilton; Michael S Rogers; Diane R Bielenberg; Mark Puder
Journal:  Angiogenesis       Date:  2018-06-28       Impact factor: 9.596

2.  Vascular Endothelial Growth Factor Enhances Compensatory Lung Growth in Piglets.

Authors:  Duy T Dao; Lorenzo Anez-Bustillos; Amy Pan; Alison A O'Loughlin; Paul D Mitchell; Gillian L Fell; Meredith A Baker; Bennet S Cho; Prathima Nandivada; Arthur P Nedder; Charles J Smithers; Nancy Chen; Robert Comeau; Kevin Holmes; Susan Kalled; Angela Norton; Bohong Zhang; Mark Puder
Journal:  Surgery       Date:  2018-09-05       Impact factor: 3.982

3.  Hypoxia-inducible factor 1α (HIF-1α) is a major determinant in the enhanced function of muscle-derived progenitors from MRL/MpJ mice.

Authors:  Krishna M Sinha; Chieh Tseng; Ping Guo; Aiping Lu; Haiying Pan; Xueqin Gao; Reid Andrews; Holger Eltzschig; Johnny Huard
Journal:  FASEB J       Date:  2019-04-10       Impact factor: 5.191

4.  Investigation of the mechanisms of VEGF-mediated compensatory lung growth: the role of the VEGF heparin-binding domain.

Authors:  Lumeng J Yu; Victoria H Ko; Duy T Dao; Jordan D Secor; Amy Pan; Bennet S Cho; Paul D Mitchell; Hiroko Kishikawa; Diane R Bielenberg; Mark Puder
Journal:  Sci Rep       Date:  2021-06-04       Impact factor: 4.379

5.  Hypoxia inducible factor 2α (HIF2α/EPAS1) is associated with development of pulmonary hypertension in severe congenital diaphragmatic hernia patients.

Authors:  Yadi Huang; Anne Boerema-de Munck; Marjon Buscop-van Kempen; Ilona Sluiter; Ronald de Krijger; Dick Tibboel; Robbert J Rottier
Journal:  Pulm Circ       Date:  2018-06-01       Impact factor: 3.017

6.  A paradoxical method to enhance compensatory lung growth: Utilizing a VEGF inhibitor.

Authors:  Duy T Dao; Lorenzo Anez-Bustillos; Sahir S Jabbouri; Amy Pan; Hiroko Kishikawa; Paul D Mitchell; Gillian L Fell; Meredith A Baker; Randolph S Watnick; Hong Chen; Michael S Rogers; Diane R Bielenberg; Mark Puder
Journal:  PLoS One       Date:  2018-12-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.